$ABSI 0.49 Noisy

Notable posts

• @wallstengine neutral 42 eng

  $ABSI reported interim Phase 1 safety data for ABS-201, its prolactin receptor antibody being developed for androgenetic alopecia. No serious adverse events were reported across 32 healthy adults, with most treatment-emergent adverse events mild. Interim PK data showed an estimated half-life of at least 65 days, supporting potential dosing of 2-3 subcutaneous doses over six months. Absci has now advanced the trial into the multiple ascending dose phase in patients with androgenetic alopecia.

  view on X →
• @wallstengine bullish 33 eng

  A @ralliesai AI-built healthcare fund is up 43.7% since June 3 Someone asked the Rallies AI agent to build a fund around healthcare AI, covering diagnostics, drug discovery, hospital data infrastructure, and AI imaging. The AI built the basket, bought the names automatically, and provided the reasoning behind every position. The agent bought: Tempus AI $TEM Absci $ABSI Recursion Pharmaceuticals $RXRX RadNet $RDNT Butterfly Network $BFLY Best performers so far: Absci $ABSI: +89.7% Butterfly Network $BFLY: +79.3% Tempus AI $TEM: +30.9% RadNet $RDNT: +24.2% Recursion Pharmaceuticals $RXRX: +7.3% The fund is now one of the popular funds on Rallies.

  view on X →